AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01350011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Innovative System
Description: In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
Study NCT01350011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Control (STC)
Description: Participants will receive self help information and referrals for counseling and for pharmacological treatment.
Study NCT03818711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication & Coping Intervention
Description: Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
Study NCT03818711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education & Check Ins
Description: Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
Study NCT02169713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral
Study NCT02886910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical observation
Description: Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
Study NCT02886910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical observation
Description: Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
Study NCT02886910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard management
Description: Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
Study NCT04879108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation
Description: Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day.
Study NCT04879108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Rehabilitation
Description: Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day.
Study NCT01266278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound
Description: Measurement of the size of the subacromial space with dynamic ultrasound.
Study NCT01266278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FASTRAK
Description: Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
Study NCT01266278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of shoulder posture by measuring
Description: Assessment of shoulder posture by measuring several angles and distances.
Study NCT02169713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral
Study NCT02169713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl
Description: Oral
Study NCT02169713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT01455233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: besivance
Description: topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
Study NCT01455233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vigamox
Description: topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
Study NCT01700881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Study NCT01700881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
Study NCT03969836 — intervention group
Intervention type: DEVICE
Intervention: NeurOS system
Description: NeurOS system pads will be placed on patients' head for monitoring.
Study NCT03242590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1021
Description: Oral testosterone undecanoate
Study NCT03766464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of TMD and pain sensitivity
Description: Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
Study NCT03766464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of SB
Description: The presence or absence of SB will be diagnosed by Polysomnography
Study NCT03766464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of AB
Description: A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
Study NCT04072835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS
Description: Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
Study NCT02944721 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetical analyses
Study NCT02272634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPL-001 160 mg
Description: twice daily \[BID\]
Study NCT02944721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chronic pain identification questionnaires
Study NCT02944721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurophysiological and psychophysical evaluations
Study NCT02944721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaires
Study NCT00776698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
Study NCT00776698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2 iv every 3 weeks for 3 cycles
Study NCT00776698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study NCT00360685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tac+MTX
Description: Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
Study NCT02272634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily \[BID\]
Study NCT03764761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC Technology - Standard of Care
Description: Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
Study NCT03764761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC Technology - non-optimal integrated arrangement
Description: Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
Study NCT03764761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC Technology - non-optimal integrated arrangement
Description: Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
Study NCT01023191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Insertion catheter
Description: Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
Study NCT01023191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open insertion Catheter
Description: Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
Study NCT00237913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
Study NCT00237913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or Quetiapine or Risperidone
Description: Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
Study NCT04460859 — intervention group
Intervention type: OTHER
Intervention: Specific lung recruitment maneuvers
Description: Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
Study NCT05671016 — intervention group
Intervention type: PROCEDURE
Intervention: MRI scans and questionnaires
Description: Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
Study NCT00611481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: a set of pre-designed Tai Chi Movements
Study NCT00611481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Lower-extremity strength training exercises
Study NCT00611481 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-Impact Exercise Control
Description: a set of chair-based low-impact exercises
Study NCT04796753 — intervention group
Intervention type: OTHER
Intervention: Basketball Injury Defense
Description: To establish a specific evaluation protocol for youth basketball players.
Study NCT01096030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: 160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
Study NCT05041881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal lens AT LISA TRI, Zeiss
Description: lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
Study NCT05041881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accommodating Tetraflex HD lens, Lenstec inc.
Description: lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
Study NCT05041881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal lens, Softec HD
Description: lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
Study NCT03246126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant™Thoracoabdominal Stent Graft System
Description: The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
Study NCT00005614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: Gemcitabine via IV
Study NCT03253835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single Group Assignment
Study NCT02191631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Description: The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
Study NCT00360685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAC + MMF
Description: Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
Study NCT00044655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study NCT01406483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Platelet reactivity assessment
Description: Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
Study NCT04428515 — intervention group
Intervention type: DEVICE
Intervention: Photoacoustic Imaging System
Description: Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
Study NCT03924206 — intervention group
Intervention type: DEVICE
Intervention: Smoke evacuation system
Description: The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
Study NCT01267721 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at various time points. Additional 92 mL blood.
Study NCT04091711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReX-C system
Description: Oral oncolytic medications are dispensed to patients via ReX-C system
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: 1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 84 mg
Description: 1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Study NCT02393443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
Study NCT02393443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
Study NCT00426712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
Description: Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
Study NCT00426712 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine (Recombinant)
Description: IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
Study NCT04581174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Description: Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
Study NCT01570803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S.M.A.R.T CONTROL Stent
Description: Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
Study NCT01570803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Stent
Description: same to SMART CONTROL Stent
Study NCT01998958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Study NCT01261052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm
Description: The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.